BCL2 interacting protein 3 pseudogene 9Genealiases: []
Q-omics provides the consensus-scored BNIP3P9 profile across patient tissues and cancer cell-line models. BNIP3P9 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, BNIP3P9 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, BNIP3P9 RNA expression shows 10,888 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUSC, KIRC, and TGCT as cancer lineages where BNIP3P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BNIP3P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BNIP3P9 survival associations across molecular data types. BNIP3P9 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BNIP3P9 RNA expression–survival associations across cancer types. High BNIP3P9 expression shows unfavorable associations in LUSC, LGG and THCA, but favorable associations in CESC, KIRC and SKCM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for BNIP3P9 RNA expression.
This table summarizes BNIP3P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BNIP3P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BNIP3P9 shows lower tumor expression in KIRC, KIRP, KICH, BRCA and PAAD and higher tumor expression in LIHC. The KIRC box plot shows higher BNIP3P9 RNA expression in normal versus tumor tissue (log2 FC = −0.331, t-test p < 0.001).
This table shows molecular features associated with BNIP3P9 in patient tissues and cancer cell lines. In patient samples, BNIP3P9 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
